WO1998048785A3 - Allelic polygene diagnosis of reward deficiency syndrome and treatment - Google Patents

Allelic polygene diagnosis of reward deficiency syndrome and treatment Download PDF

Info

Publication number
WO1998048785A3
WO1998048785A3 PCT/US1998/008684 US9808684W WO9848785A3 WO 1998048785 A3 WO1998048785 A3 WO 1998048785A3 US 9808684 W US9808684 W US 9808684W WO 9848785 A3 WO9848785 A3 WO 9848785A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
precursor
phenylalanine
dopamine
enkephalinase
Prior art date
Application number
PCT/US1998/008684
Other languages
French (fr)
Other versions
WO1998048785A9 (en
WO1998048785A2 (en
Inventor
Kenneth Blum
David E Comings
John L Ivy
Original Assignee
Kenneth Blum Inc
Univ Texas
Hope Nat Medical Center
Kenneth Blum
David E Comings
John L Ivy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth Blum Inc, Univ Texas, Hope Nat Medical Center, Kenneth Blum, David E Comings, John L Ivy filed Critical Kenneth Blum Inc
Priority to JP54736498A priority Critical patent/JP2002511850A/en
Priority to EP98920019A priority patent/EP0979092A2/en
Priority to AU72677/98A priority patent/AU7267798A/en
Priority to IL13263498A priority patent/IL132634A0/en
Priority to CA002288990A priority patent/CA2288990A1/en
Publication of WO1998048785A2 publication Critical patent/WO1998048785A2/en
Publication of WO1998048785A3 publication Critical patent/WO1998048785A3/en
Publication of WO1998048785A9 publication Critical patent/WO1998048785A9/en
Priority to NO995257A priority patent/NO995257L/en
Priority to IS5233A priority patent/IS5233A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Enhancement of attentional processing is attained by administration of an endorphinase inhibitor or enkephalinase inhibitor and optionally, a dopamine precursor, or a serotonin precursor, a GABA precursor, or an endorphin or enkephalinase releaser, or certain herbal compounds including Rhodiola rosea extract (Pharmaline) and/or Huperzine. These components promote restoration of normal neurotransmitter function and the components combined enhance the release of dopamine at the nucleus accumbens and are non-addictive. Use of the dopamine precursors L-phenylalanine, or L-Tyrosine, the enkephalinase inhibitor D-phenylalanine, and/or the serotonin precursor -hydroxytryptophan and a natural acetylcholenesterase inhibitor and chromium salts (i.e. picolinate, nicotinate, etc.) is especially preferred, but not limited to assist in relieving symptoms associated with brain phenylalanine deficiency.
PCT/US1998/008684 1997-04-29 1998-04-29 Allelic polygene diagnosis of reward deficiency syndrome and treatment WO1998048785A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP54736498A JP2002511850A (en) 1997-04-29 1998-04-29 Allelic polygenic diagnosis and treatment of reward deficiency syndrome
EP98920019A EP0979092A2 (en) 1997-04-29 1998-04-29 Allelic polygene diagnosis of reward deficiency syndrome and treatment
AU72677/98A AU7267798A (en) 1997-04-29 1998-04-29 Allelic polygene diagnosis of reward deficiency syndrome and treatment
IL13263498A IL132634A0 (en) 1997-04-29 1998-04-29 Allelic polygene diagnosis of reward deficiency syndrome and treatment
CA002288990A CA2288990A1 (en) 1997-04-29 1998-04-29 Allelic polygene diagnosis of reward deficiency syndrome and treatment
NO995257A NO995257L (en) 1997-04-29 1999-10-28 Procedures and materials for diagnosis and treatment of Reward Deficiency Syndrome
IS5233A IS5233A (en) 1997-04-29 1999-10-28 Diagnosis of reward deficiency syndrome and its preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4439497P 1997-04-29 1997-04-29
US60/044,394 1997-04-29

Publications (3)

Publication Number Publication Date
WO1998048785A2 WO1998048785A2 (en) 1998-11-05
WO1998048785A3 true WO1998048785A3 (en) 1999-04-01
WO1998048785A9 WO1998048785A9 (en) 1999-05-20

Family

ID=21932148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008684 WO1998048785A2 (en) 1997-04-29 1998-04-29 Allelic polygene diagnosis of reward deficiency syndrome and treatment

Country Status (10)

Country Link
EP (1) EP0979092A2 (en)
JP (1) JP2002511850A (en)
KR (1) KR20010020422A (en)
CN (1) CN1261801A (en)
AU (1) AU7267798A (en)
CA (1) CA2288990A1 (en)
IL (1) IL132634A0 (en)
IS (1) IS5233A (en)
NO (1) NO995257L (en)
WO (1) WO1998048785A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US6955873B1 (en) * 2000-08-04 2005-10-18 Kenneth Blum Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
GB9927806D0 (en) * 1999-11-24 2000-01-26 Isis Innovation Genetic indicators of tobacco consumption
ATE329620T1 (en) * 2000-12-01 2006-07-15 Be Able Llc BEHAVIOR CHEMOTHERAPY
ITRM20010218A1 (en) * 2001-04-23 2002-10-23 Sigma Tau Healthscience Spa COMPOSITION FOR THE PREVENTION OR TREATMENT OF LEARNING DISORDERS IN CHILDREN AFFECTED BY ATTENTION DEFICIT AND HYPERACTIVE
US8142799B2 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco High potency clinical anti-craving treatment and method of use
US8142800B1 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco Oral high potency clinical anti-craving treatment and method of use
CN101495498B (en) * 2005-02-07 2013-09-18 基因信息公司 Mild osteoarthritis biomarkers and uses thereof
WO2008038710A1 (en) 2006-09-28 2008-04-03 Mitsubishi Electric Corporation Fault detector, fault detection method, and fault detection program
US20110189161A1 (en) * 2008-06-21 2011-08-04 Kenneth Blum Nutrigenomics methods and compositions
WO2010005303A2 (en) * 2008-07-07 2010-01-14 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum New indicators of human longevity and biological ageing rate
AU2011234422B2 (en) 2010-04-01 2015-11-05 Ecole Polytechnique Federale De Lausanne (Epfl) Device for interacting with neurological tissue and methods of making and using the same
US20120022610A1 (en) * 2010-04-22 2012-01-26 Kenneth Blum Devices for Delivering Neuro Electro Adaptive Therapy NEAT
US9727691B2 (en) 2011-09-30 2017-08-08 Tokyo Metropolitan Institute Of Medical Science Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic AMP responsive element binding protein gene
JP2015067581A (en) * 2013-09-30 2015-04-13 国立大学法人京都大学 Probe for multiple resonance
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
CN103990106A (en) * 2014-06-11 2014-08-20 河北医科大学 Application of cholecystokinin octapeptide in medicine preparation
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
CN104846015B (en) * 2015-05-27 2018-03-27 深圳先进技术研究院 The composition of GABA serotonergic neurons in special heat nucleus accumbens septi and its application in schizophrenia difference behavior is improved
CN109069824B (en) * 2016-02-02 2022-09-16 阿莱瓦神经治疗股份有限公司 Treatment of autoimmune diseases using deep brain stimulation
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device
CN109316196B (en) * 2018-12-12 2022-07-19 上海市精神卫生中心（上海市心理咨询培训中心） Amphetamine stimulant craving assessment method based on virtual reality and electroencephalogram monitoring
CN110507294B (en) * 2019-08-07 2022-02-08 北京安龙脉德医学科技有限公司 First-aid system based on internet information transmission
CN110991044B (en) * 2019-12-03 2023-02-24 北京机电工程研究所 Agent modeling-based aircraft system task reliability assessment method
CN112862751B (en) * 2020-12-30 2022-05-31 电子科技大学 Automatic diagnosis device for autism
CN113332299A (en) * 2021-05-27 2021-09-03 广东湛江海洋医药研究院 Application of salidroside in relieving glucocorticoid-induced osteoporosis
KR102434668B1 (en) * 2022-03-02 2022-08-22 주식회사 국개대표 Feed for pets that can improve separation anxiety symptoms and manufacturing thereof
CN115830001B (en) * 2022-12-22 2023-09-08 抖音视界有限公司 Intestinal tract image processing method and device, storage medium and electronic equipment

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000430A2 (en) * 1985-07-22 1987-01-29 Matrix Technologies, Inc. Enkephalinase and endorphinase inhibitors as anti-craving compositions
US5013752A (en) * 1989-03-10 1991-05-07 Dobbins John P Prevention and treatment of alcoholism by the use of dietary chromium
US5019594A (en) * 1989-11-28 1991-05-28 Interneuron Pharmaceuticals, Inc. Method for decreasing appetite
US5164384A (en) * 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula
US5189064A (en) * 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
WO1995011034A1 (en) * 1993-10-22 1995-04-27 Keown Wendy J Composition for weight reduction containing ephedrine and a mineral salt or chelate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000430A2 (en) * 1985-07-22 1987-01-29 Matrix Technologies, Inc. Enkephalinase and endorphinase inhibitors as anti-craving compositions
US5189064A (en) * 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US5013752A (en) * 1989-03-10 1991-05-07 Dobbins John P Prevention and treatment of alcoholism by the use of dietary chromium
US5019594A (en) * 1989-11-28 1991-05-28 Interneuron Pharmaceuticals, Inc. Method for decreasing appetite
US5164384A (en) * 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula
WO1995011034A1 (en) * 1993-10-22 1995-04-27 Keown Wendy J Composition for weight reduction containing ephedrine and a mineral salt or chelate

Also Published As

Publication number Publication date
AU7267798A (en) 1998-11-24
EP0979092A2 (en) 2000-02-16
WO1998048785A9 (en) 1999-05-20
WO1998048785A2 (en) 1998-11-05
IS5233A (en) 1999-10-28
KR20010020422A (en) 2001-03-15
CN1261801A (en) 2000-08-02
CA2288990A1 (en) 1998-11-05
JP2002511850A (en) 2002-04-16
NO995257D0 (en) 1999-10-28
IL132634A0 (en) 2001-03-19
NO995257L (en) 1999-12-27

Similar Documents

Publication Publication Date Title
WO1998048785A3 (en) Allelic polygene diagnosis of reward deficiency syndrome and treatment
Walker et al. The γ‐aminobutyric acid‐B receptor agonist baclofen attenuates responding for ethanol in ethanol‐dependent rats
Stromberg et al. Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption
SE9500422D0 (en) New oral pharmaceutical dosage forms
WO2000059487A3 (en) Flupirtine in the treatment of fibromyalgia and related conditions
BR9607926A (en) Pharmaceutical composition for the treatment of hyperphosphatemia use of lanthanum carbonate process for the preparation of lanthanum carbonate and lanthanum carbonate
WO1998005331A3 (en) Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
ATE394107T1 (en) PREVENTION AND TREATMENT OF COLON ADENOMA OR COLON MICROADENOMA WITH 6-FLUORUROSODEOXYCHOLIC ACID
WO2001045668A3 (en) Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
EP0959878A4 (en) Method for treating renal failure
Binning Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery
AU1718400A (en) Method for treating pain
DE69719931T2 (en) Use of acetylcysteine in the manufacture of a medicament for the treatment of chronic ulcers
IL134163A0 (en) Chromium/biotin treatment of type ii diabetes
JP2002519391A5 (en)
NO985676L (en) Compounds with colchicine structure, their use as drugs and drugs
DE3882712D1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COCOA ADDICTION.
AU2003292006A1 (en) 3,5,3'-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
WO2006124544A3 (en) Use of tyrosine kinase inhibitors in the treatment of metabolic disorders
Wilens et al. Attention-deficit hyperactivity disorder and the substance use disorders in ADHD
NO20075831L (en) Crystalline solid and amorphous forms of (-) - halophenate
Ghose et al. A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache
EP0345883A3 (en) Use of dapiprazole for the manufacture of a pharmaceutical composition inhibiting the development of tolerance in the analgesic treatment with morphine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 132634

Country of ref document: IL

Ref document number: 98806484.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 649, CLAIMS, REPLACED BY CORRECTED PAGE 649; PAGES 650-653, CLAIMS, REPLACED BY NEW PAGES 650-653; PAGE 654, CLAIMS, ADDED; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2288990

Country of ref document: CA

Ref document number: 2288990

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1999-3836

Country of ref document: CZ

Ref document number: PA/a/1999/009902

Country of ref document: MX

Ref document number: 72677/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 500688

Country of ref document: NZ

Ref document number: 1019997010047

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1998920019

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 199900984

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: P-621/99

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 09423040

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998920019

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: PV1999-3836

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997010047

Country of ref document: KR

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI9809588

Country of ref document: BR

Free format text: PEDIDO RETIRADO TENDO EM VISTA O NAO CUMPRIMENTO DAS DETERMINACOES REFERENTES A ENTRADA NA FASE NACIONAL FACE AO ARQUIVAMENTO DA PETICAO NO 009969 DE 29/10/1999 - ART. 216 DA LPI.

WWR Wipo information: refused in national office

Ref document number: 1019997010047

Country of ref document: KR